-
公开(公告)号：US20220280501A1
公开(公告)日：2022-09-08
申请号：US17685138
申请日：2022-03-02
IPC分类号： A61K31/4745 , C12Q1/6876
摘要： A method of dosing LSD in treating patients, by assessing genetic characteristics in the patient before LSD use, administering LSD to the patient based on the patient genetics, and producing maximum positive subjective acute effects in the subject and/or reducing anxiety and negative effects. A method of determining a preferred dose of LSD, by determining metabolic and genetic markers in a patient (such as by assessing CYP2D6 activity and/or assessing 5HTR1A rs6295 and 5HTR2A rs6313 genotypes in a patient), adjusting a dose of LSD based on the metabolic activity and genetic profile, administering the dose of LSD to the patient, and producing maximum positive subjective acute effects in the subject and/or reducing anxiety and negative effects. A method of determining a dose of LSD based on an assessment of the presence of CYP2D6 inhibitors.
-
公开(公告)号：US20220273628A1
公开(公告)日：2022-09-01
申请号：US17672670
申请日：2022-02-15
IPC分类号： A61K31/437 , A61K45/06 , A61P25/22
摘要： A method of treating anxiety disorders specifically not associated with causes such as a life-threatening serious somatic illness, by administering a psychedelic to an individual, and treating anxiety and specifically causing reductions in the rating scale score measures of anxiety (STAI global or state or trait anxiety) and/or measures of depression (HDRS or BDI scores) and/or measures of general psychological distress (SCL-90 ratings) in the patient for several weeks beyond administration of the psychedelic. A method of treating anxiety, by administering a psychedelic (preferably LSD) to an individual having anxiety not associated with causes such as a life-threatening serious somatic illness, and inducing positive acute drug effects and positive long-term therapeutic effects in the individual.
-
公开(公告)号：US20190388155A1
公开(公告)日：2019-12-26
申请号：US16563280
申请日：2019-09-06
发明人： Philippe Cattin , Gregory Jost , Jonas Walti
摘要： A method of controlling a surgical intervention to a bone comprises obtaining a three-dimensional image or multiplanar reconstruction of the bone, defining a position and an axis of intervention on the three-dimensional image or multiplanar reconstruction of the bone, and controlling an orientation of an intervention instrument equipped with an orientation sensor during the surgical intervention by evaluating a signal provided by the orientation sensor. The method further comprises referencing the intervention instrument with respect to the bone before the surgical intervention by arranging the intervention instrument in relation to an anatomic landmark and rotating the orientation sensor into a predefined position. The method allows for efficiently achieving correct orientation and position of the intervention instrument in bone surgical intervention. Furthermore, the method provides an efficient real-time control at comparably low efforts. Still further, with the method radiation exposure to the operational staff as well as patients can be reduced.
-
公开(公告)号：US10188499B2
公开(公告)日：2019-01-29
申请号：US15022212
申请日：2014-09-18
发明人： Bernhard Winkler , Martin Grapow , Friedrich Eckstein , Aldo Ferrari , Dimos Poulikakos , Simone Bottan , Maximilian Fischer , Tobias Lendenmann
摘要： The invention relates to an artificial vascular graft comprising a primary scaffold structure encompassing an inner space of the artificial vascular graft, said primary scaffold structure having an inner surface facing towards said inner space and an outer surface facing away from said inner space, a coating on said inner surface, wherein a plurality of grooves is comprised in said coating of said inner surface. The primary scaffold structure comprises further a coating on said outer surface. The primary scaffold structure and the coating on said inner surface and on said outer surface are d designed in such a way that cells, in particular progenitor cells, can migrate from the periphery of said artificial vascular graft through said outer surface of said coating, said primary scaffold structure and said inner surface to said inner space, if the artificial vascular graft is used as intended. The invention relates further to a method for providing said graft.
-
公开(公告)号：US20160228233A1
公开(公告)日：2016-08-11
申请号：US15022212
申请日：2014-09-18
发明人： Bernhard WINKLER , Martin GRAPOW , Friedrich ECKSTEIN , Aldo FERRARI , Dimos POULIKAKOS , Maximilian FISCHER , Tobias LENDENMANN
CPC分类号： A61F2/06 , A61F2/062 , A61F2/07 , A61F2/90 , A61F2002/0086 , A61F2002/068 , A61F2002/072 , A61F2210/0014 , A61F2210/0076 , A61F2250/0026 , A61F2250/003 , A61F2250/0051 , A61F2310/00011 , A61F2310/00982 , C12N1/20
摘要： The invention relates to an artificial vascular graft comprising a primary scaffold structure encompassing an inner space of the artificial vascular graft, said primary scaffold structure having an inner surface facing towards said inner space and an outer surface facing away from said inner space, a coating on said inner surface, wherein a plurality of grooves is comprised in said coating of said inner surface. The primary scaffold structure comprises further a coating on said outer surface. The primary scaffold structure and the coating on said inner surface and on said outer surface are d designed in such a way that cells, in particular progenitor cells, can migrate from the periphery of said artificial vascular graft through said outer surface of said coating, said primary scaffold structure and said inner surface to said inner space, if the artificial vascular graft is used as intended. The invention relates further to a method for providing said graft.
摘要翻译： 本发明涉及一种人造血管移植物，其包括包含人造血管移植物的内部空间的主要支架结构，所述主要支架结构具有面向所述内部空间的内表面和背离所述内部空间的外表面， 所述内表面，其中在所述内表面的所述涂层中包括多个凹槽。 主支架结构还包括在所述外表面上的涂层。 所述内表面和所述外表面上的主要支架结构和涂层的设计使得细胞，特别是祖细胞可以从所述人造血管移植物的周边迁移穿过所述涂层的外表面，所述 主要支架结构和所述内表面到所述内部空间，如果人造血管移植物按预期使用。 本发明进一步涉及提供所述移植物的方法。
-
6.发明授权公开(公告)号：US11963946B2
公开(公告)日：2024-04-23
申请号：US17238088
申请日：2021-04-22
摘要： A method of enhancing positive effects of a psychedelic, by inducing a positive psychological state in an individual with an empathogen/entactogen, administering a psychedelic to the individual, and enhancing a positive response to the psychedelic. A composition including an entactogen/empathogen and a serotonergic psychedelic in the same dosage form or administered as separate compositions within a combination treatment schedule. A method of enhancing positive effects of a psychedelic, by inducing the release of endogenous monoamines, and subsequently stimulating 5-HT2A receptors.
-
公开(公告)号：US20230039395A1
公开(公告)日：2023-02-09
申请号：US17734601
申请日：2022-05-02
IPC分类号： A61K49/00 , A61K31/48 , A61K31/675
摘要： A method of treating a patient with a psychedelic, by administering either a dose of LSD to the patient that is equivalent to a known dose of psilocybin with desired acute and therapeutic effects, or administering a dose of psilocybin to the patient that is equivalent to a known dose of LSD with desired acute and therapeutic effects. A method of treating a patient with LSD, by administering a dose of LSD to the patient equivalent to those of psilocybin known to be associated with positive long-term therapeutic outcomes. A method of determining a dose of a psychedelic or the dose-equivalence to another psychedelic to be administered to an individual, by administering a dose of a psychedelic to an individual, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual.
-
公开(公告)号：US20220387456A1
公开(公告)日：2022-12-08
申请号：US17692105
申请日：2022-03-10
IPC分类号： A61K31/675 , A61K31/343 , A61P25/24 , A61P25/22
摘要： A method of enhancing positive effects of a psychedelic, by pretreating an individual with an antidepressant, administering a psychedelic to the individual, and inducing a more positive psychological state in the individual with the antidepressant-psychedelic combination compared with the psychedelic alone. A method of enhancing positive effects of a psychedelic, by inhibiting serotonin transport in an individual, increasing levels of endogenous monoamines in the individual, and stimulating 5-HT2A receptors in the individual. A composition including an antidepressant and a psychedelic in the same dosage form.
-
公开(公告)号：US20220265582A1
公开(公告)日：2022-08-25
申请号：US17675894
申请日：2022-02-18
IPC分类号： A61K31/137 , A61P25/00
摘要： A method of inducing psychedelic states in an individual, by administering mescaline, a salt thereof, analogs thereof, or derivatives thereof to the individual, and inducing a psychedelic state in the individual. A method of therapy, by administering an intermediate “good effect dose” of mescaline, salt of mescaline, analogs thereof, or derivatives thereof to an individual, and inducing positive acute drug effects that are known to be associated with more positive long-term responses in psychiatric patients. A method of therapy, by administering an “ego-dissolution” dose of mescaline, a salt of mescaline, analogs thereof, or derivatives thereof to an individual, and providing the experience of ego-dissolution.
-
10.发明申请公开(公告)号：US20210346341A1
公开(公告)日：2021-11-11
申请号：US17238088
申请日：2021-04-22
摘要： A method of enhancing positive effects of a psychedelic, by inducing a positive psychological state in an individual with an empathogen/entactogen, administering a psychedelic to the individual, and enhancing a positive response to the psychedelic. A composition including an entactogen/empathogen and a serotonergic psychedelic in the same dosage form or administered as separate compositions within a combination treatment schedule. A method of enhancing positive effects of a psychedelic, by inducing the release of endogenous monoamines, and subsequently stimulating 5-HT2A receptors.
-
-
-
-
-
-
-
-
-
搜索结果
37 条记录 (耗时 0.017 秒)
